GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » PB Ratio

Axsome Therapeutics (STU:19X) PB Ratio : 49.66 (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Axsome Therapeutics's share price is €85.82. Axsome Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was €1.73. Hence, Axsome Therapeutics's PB Ratio of today is 49.66.

The historical rank and industry rank for Axsome Therapeutics's PB Ratio or its related term are showing as below:

STU:19X' s PB Ratio Range Over the Past 10 Years
Min: 10.08   Med: 24.26   Max: 176.19
Current: 46.98

During the past 11 years, Axsome Therapeutics's highest PB Ratio was 176.19. The lowest was 10.08. And the median was 24.26.

STU:19X's PB Ratio is ranked worse than
98.52% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs STU:19X: 46.98

During the past 12 months, Axsome Therapeutics's average Book Value Per Share Growth Rate was -66.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 9.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 79.00% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Axsome Therapeutics was 137.10% per year. The lowest was -76.60% per year. And the median was 36.20% per year.

Back to Basics: PB Ratio


Axsome Therapeutics PB Ratio Historical Data

The historical data trend for Axsome Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics PB Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.24 26.44 84.86 29.70 19.17

Axsome Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.80 19.17 26.86 37.07 46.48

Competitive Comparison of Axsome Therapeutics's PB Ratio

For the Biotechnology subindustry, Axsome Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's PB Ratio falls into.



Axsome Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Axsome Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=85.82/1.728
=49.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Axsome Therapeutics  (STU:19X) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Axsome Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics Business Description

Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines